Search

SGS518

SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

Madecassic acid

IPH 2101

IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

KAI-1455

In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult. … Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia.

BOS172722

The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects. … [A187120] An in vivo study combined BOS172722 with [Paclitaxel] for the treatment of triple hormone receptor negative breast cancer, and demonstrated promising synergistic effects.[A187123]

19-Nor-5-androstenedione

It is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports. … 19-Nor-5-andorstenedione is a prohormone which has the potential to affect bodily levels of testosterone once metabolized in vivo.

Dihydrotachysterol

A vitamin D that can be regarded as a reduction product of vitamin D2.

GPI-1485

GPI 1485 is being studied in phase 2 clinical trials for the treatment of Parkinson's disease and post-prostatectomy erectile dysfunction and in pre-clinical development for HIV related dementia and neuropathy … In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without affecting normal, healthy nerves.

Nialamide

Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

Sulfate ion